Pharmacokinetics study of Cefazolin in haemodialysis (CEFAZODIAL) - DR220268

Centre Hospitalier Regional Universitaire De Tours0 个研究点目标入组 50 人开始时间: 2023年7月13日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Subjects aged 18 years or over, On chronic intermittent dialysis, With a stated indication for initiation of cefazolin either : 1/ For probabilistic treatment of a clinical presentation suggestive of SAMS infection 2/ For treatment of Gram-positive cocci bacteremia, With the possibility of taking peripheral blood samples or blood samples from the dialysis machine until the next dialysis session at 48 hours, Covered by or entitled to social security, Signed informed consent form

•Pregnant or breastfeeding woman, Dialysis lasting less than 3 hours, which most often corresponds to acute dialysis or the start of chronic dialysis which fundamentally changes the elimination profile, Allergy to cephalosporin and penicillin antibiotics (5-10% risk of cross-reactivity), Non-anuric subjects with inhibitors of tubular creatinine secretion: Curative-dose trimethoprim, Cimetidine, Ritonavir, Rilpivirine, Dolutegravir, Cobicistat, Patient following any measures of legal presentation

发起方